These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 12671460)

  • 21. Peptide-based candidate vaccine against respiratory syncytial virus.
    Yusibov V; Mett V; Mett V; Davidson C; Musiychuk K; Gilliam S; Farese A; Macvittie T; Mann D
    Vaccine; 2005 Mar; 23(17-18):2261-5. PubMed ID: 15755607
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Respiratory syncytial virus-induced airway hyperresponsiveness is independent of IL-13 compared with that induced by allergen.
    Park JW; Taube C; Yang ES; Joetham A; Balhorn A; Takeda K; Miyahara N; Dakhama A; Donaldson DD; Gelfand EW
    J Allergy Clin Immunol; 2003 Dec; 112(6):1078-87. PubMed ID: 14657862
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevention and treatment of respiratory syncytial virus infection in infants: an update.
    Venkatesh MP; Weisman LE
    Expert Rev Vaccines; 2006 Apr; 5(2):261-8. PubMed ID: 16608425
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Respiratory syncytial virus and innate immunity: a complex interplay of exploitation and subversion.
    Johnson TR
    Expert Rev Vaccines; 2006 Jun; 5(3):371-80. PubMed ID: 16827621
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunogenicity and efficacy of codon optimized DNA vaccines encoding the F-protein of respiratory syncytial virus.
    Ternette N; Tippler B; Uberla K; Grunwald T
    Vaccine; 2007 Oct; 25(41):7271-9. PubMed ID: 17825960
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of respiratory syncytial virus: antiviral therapies.
    Jafri HS
    Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S89-92; discussion S92-3. PubMed ID: 12671458
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Respiratory syncytial virus and influenza virus infections: observations from tissues of fatal infant cases.
    Welliver TP; Reed JL; Welliver RC
    Pediatr Infect Dis J; 2008 Oct; 27(10 Suppl):S92-6. PubMed ID: 18820587
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Young infants can develop protective levels of neutralizing antibody after infection with respiratory syncytial virus.
    Shinoff JJ; O'Brien KL; Thumar B; Shaw JB; Reid R; Hua W; Santosham M; Karron RA
    J Infect Dis; 2008 Oct; 198(7):1007-15. PubMed ID: 18702606
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Respiratory syncytial virus infections: characteristics and treatment.
    Chidgey SM; Broadley KJ
    J Pharm Pharmacol; 2005 Nov; 57(11):1371-81. PubMed ID: 16259768
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The future of respiratory syncytial virus vaccine development.
    Polack FP; Karron RA
    Pediatr Infect Dis J; 2004 Jan; 23(1 Suppl):S65-73. PubMed ID: 14730272
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Optimization of plasmid-only rescue of highly attenuated and temperature-sensitive respiratory syncytial virus (RSV) vaccine candidates for human trials.
    Kaur J; Tang RS; Spaete RR; Schickli JH
    J Virol Methods; 2008 Nov; 153(2):196-202. PubMed ID: 18722472
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An immunocompromised BALB/c mouse model for respiratory syncytial virus infection.
    Kong X; Hellermann GR; Patton G; Kumar M; Behera A; Randall TS; Zhang J; Lockey RF; Mohapatra SS
    Virol J; 2005 Feb; 2():3. PubMed ID: 15701174
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression of interleukin-4 by recombinant respiratory syncytial virus is associated with accelerated inflammation and a nonfunctional cytotoxic T-lymphocyte response following primary infection but not following challenge with wild-type virus.
    Bukreyev A; Belyakov IM; Prince GA; Yim KC; Harris KK; Berzofsky JA; Collins PL
    J Virol; 2005 Aug; 79(15):9515-26. PubMed ID: 16014914
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of primary and secondary low-grade respiratory syncytial virus infections in a murine model of asthma.
    Kondo Y; Matsuse H; Machida I; Kawano T; Saeki S; Tomari S; Obase Y; Fukushima C; Kohno S
    Clin Exp Allergy; 2004 Aug; 34(8):1307-13. PubMed ID: 15298574
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Respiratory syncytial virus disease mechanisms implicated by human, animal model, and in vitro data facilitate vaccine strategies and new therapeutics.
    Moore ML; Peebles RS
    Pharmacol Ther; 2006 Nov; 112(2):405-24. PubMed ID: 16820210
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pulmonary delivery of respiratory syncytial virus DNA vaccines using macroaggregated albumin particles.
    Harcourt JL; Anderson LJ; Sullender W; Tripp RA
    Vaccine; 2004 Jun; 22(17-18):2248-60. PubMed ID: 15149784
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants.
    Karron RA; Wright PF; Belshe RB; Thumar B; Casey R; Newman F; Polack FP; Randolph VB; Deatly A; Hackell J; Gruber W; Murphy BR; Collins PL
    J Infect Dis; 2005 Apr; 191(7):1093-104. PubMed ID: 15747245
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Experimental infection of humans with A2 respiratory syncytial virus.
    Lee FE; Walsh EE; Falsey AR; Betts RF; Treanor JJ
    Antiviral Res; 2004 Sep; 63(3):191-6. PubMed ID: 15451187
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunization strategies for the prevention of pneumovirus infections.
    Bennett N; Ellis J; Bonville C; Rosenberg H; Domachowske J
    Expert Rev Vaccines; 2007 Apr; 6(2):169-82. PubMed ID: 17408367
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Induction of mucosal B-cell memory by intranasal immunization of mice with respiratory syncytial virus.
    Valosky J; Hishiki H; Zaoutis TE; Coffin SE
    Clin Diagn Lab Immunol; 2005 Jan; 12(1):171-9. PubMed ID: 15643003
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.